April 19, 2024 14:29 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Maldives opposition demands President Muizzu's impeachment over leaked reports alleging corruption by him | AAP claims conspiracy to kill Arvind Kejriwal after mango eating row | India successfully tests Indigenous Technology Subsonic Cruise Missile | Telangana missionary school vandalised after students questioned over saffron attire | Shilpa Shetty's husband Raj Kundra's properties attached by ED in Bitcoin scam
US phase 3 trial data shows 79% vaccine efficacy against symptomatic COVID-19: AstraZeneca AstraZeneca
Image Credit: Wikimedia Commons

US phase 3 trial data shows 79% vaccine efficacy against symptomatic COVID-19: AstraZeneca

India Blooms News Service | @indiablooms | 22 Mar 2021, 10:09 pm

Ontario/IBNS: Advanced trial data from a US study on AstraZeneca coronavirus vaccine showed it is 79 per cent effective at preventing symptomatic COVID-19 and was 100 per cent effective in halting severe disease and hospitalization, said AstraZeneca in a statement on Monday.

It was reported by the investigators that the vaccine was effective across adults of all ages, including older people, which other countries with previous studies had failed to establish.

"These findings reconfirm previous results observed," said Ann Falsey of the University of Rochester School of Medicine, who helped lead the trial. "It's exciting to see similar efficacy results in people over 65 for the first time," CBC News reported. 

Also, no safety concerns related to the vaccine were identified by AstraZeneca's experts, including a rare blood clot that was identified in Europe.

It was found by the scientists that there was no increased risk of clots among the more than 20,000 people who got at least one dose of the shot, which was developed with Oxford University. 

"Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%. Amongst participants in the interim analysis, approximately 79% were white/Caucasian, 8% black/African American, 4% native American and 4% Asian, and 22% of participants were Hispanic," the pharmaceutical company said in a statement.

Although the vaccine has been approved for use in 50 countries, including Canada, it has not yet been approved in the US.

Canada is expected to receive 1.5 million doses of the AstraZeneca-Oxford product from the U.S. government this week.
 

(Reporting by Asha Bajaj)

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.